Modulation of antigenic phenotype in cultured human osteoblast-like cells by FGFb, TGFbeta1, PDGF-BB, IL-2, IL-1beta, LPS and IFNgamma.
OBJECTIVE
Recent reports demonstrated that osteoblast-like cells can also exert activities directly associated with the immune system (cytokine synthesis, antigen presentation, phagocytosis and stimulation of T lymphocytes). The present study aimed to analyze the effect of Transforming growth factorbeta1 (TGFbeta1), Fibroblast growth factor basic (FGFb), Platelet-derived growth factor-BB (PDGF-BB), Interleukin-1beta (IL-1beta), Interleukin-2 (IL-2), Lipopolysaccharide (LPS) and Interferon-gamma (IFNgamma) on the expression on osteoblast-like cells of antigens involved in antigen presentation.


METHODS
Flow cytometry was used to investigate whether the growth factors FGFb, TGFbeta1, PDGF-BB, IL-2, IL-1beta, LPS and IFNgamma modulate the expression on cultured human osteoblast-like cells of different antigens involved in antigen-presentation and T cell activation.


RESULTS
TGFbeta1 treatment significantly reduced the expression of CD54 and CD86. IL-1beta treatment significantly enhanced the expression of CD54, CD86 and HLA-DR. LPS and IFNgamma treatments produced a major increase in CD54, CD80, CD86 and HLA-DR expression. Expression of these antigen-presenting molecules was not significantly modified by FGFb, PDGF-BB or IL-2 treatment.
Pérez
E
E
Department of Nursing, Physiology Section, University of Granada, E-18012, Granada, Spain.
García-Martínez
O
O
Arroyo-Morales
M
M
Reyes-Botella
C
C
Ruiz
C
C
D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D000077214:Becaplermin; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology*; D053583:Interleukin-1beta / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology*
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D016207:Cytokines; D006684:HLA-DR Antigens; D053583:Interleukin-1beta; D007376:Interleukin-2; D008070:Lipopolysaccharides; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D053773:Transforming Growth Factor beta1; D016222:Fibroblast Growth Factor 2; D018799:Intercellular Adhesion Molecule-1; D000077214:Becaplermin; D007371:Interferon-gamma